vanda pharmaceuticals inc (VNDA) Key Developments
Vanda Pharmaceuticals Inc. Announces Marketing Authorization Application for Oral HETLIOZTM (tasimelteon) Capsules
Jun 3 14
Vanda Pharmaceuticals Inc. announced that its Marketing Authorization Application for oral HETLIOZTM (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ™ has been granted orphan drug designation for the treatment of Non-24 in blind people with no light perception from the European Commission. HETLIOZ™ was approved by the FDA in January 2014 and is available through specialty pharmacies in the U.S.
Vanda Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:30 AM
May 21 14
Vanda Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Mihael H. Polymeropoulos, Founder, Chief Executive Officer, President and Director.
Vanda Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 09:00 AM
May 14 14
Vanda Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 09:00 AM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.
Vanda Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014; Provides Financial Guidance for the Full Year of 2014
May 8 14
Vanda Pharmaceuticals, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenues of $9.143 million against $8.068 million a year ago. Loss from operations was $26.578 million against $4.565 million a year ago. Loss before tax benefit was $26.533 million against $4.519 million a year ago. Net loss was $26.533 million or $0.79 per diluted share against $4.519 million or $0.16 per diluted share a year ago. Net cash used in operating activities was $23.904 million against $9.125 million a year ago.
The company provided investors with the following financial guidance for the full year of 2014. Total operating expenses are expected to be between $110 million and $120 million. This includes intangible asset amortization of $2.5 million and between $6 million and $8 million of noncash stock-based compensation. Total 2013 operating expenses were $54.3 million. For the full year 2014, expenses are expected to reflect lower research and development spending as compared to 2013 and an increase in commercial spending to support the commercial launch of HETLIOZ in the U.S.
Vanda Pharmaceuticals, Inc. to Report Q1, 2014 Results on May 08, 2014
Apr 24 14
Vanda Pharmaceuticals, Inc. announced that they will report Q1, 2014 results at 9:00 AM, Eastern Standard Time on May 08, 2014